Phesi, a clinical development analytics company, has released its mid-year analysis for 2024.
The study analyzed 66,935 clinical trials worldwide and found that the most researched conditions now include breast cancer, solid tumor, stroke, prostate cancer, and type 2 diabetes.
The rise of type 2 diabetes research is attributed to increased interest in GLP-1s for treating conditions like obesity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze